2023
Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer
Cao A, Cartmel B, Li F, Gottlieb L, Harrigan M, Ligibel J, Gogoi R, Schwartz P, Esserman D, Irwin M, Ferrucci L. Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer. JAMA Network Open 2023, 6: e2326463. PMID: 37526937, PMCID: PMC10394582, DOI: 10.1001/jamanetworkopen.2023.26463.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyAerobic exercise interventionAttention control armExercise intervention armExercise interventionOvarian cancerControl armIntervention armSecondary analysisCIPN symptomsPeripheral neuropathyLifestyle StudyTreatment of CIPNModerate-intensity aerobic exerciseStandard oncology careEffects of exerciseSevere adverse effectsBetween-group differencesAmerican Cancer SocietyQuality of lifeAttention controlCIPN severityPrimary outcomeOncology careAerobic exercise
2018
Concordance of cancer registry and self-reported race, ethnicity, and cancer type: a report from the American Cancer Society’s studies of cancer survivors
Layne TM, Ferrucci LM, Jones BA, Smith T, Gonsalves L, Cartmel B. Concordance of cancer registry and self-reported race, ethnicity, and cancer type: a report from the American Cancer Society’s studies of cancer survivors. Cancer Causes & Control 2018, 30: 21-29. PMID: 30392148, DOI: 10.1007/s10552-018-1091-3.Peer-Reviewed Original Research
2016
Health-related quality of life in ovarian cancer survivors: Results from the American Cancer Society's Study of Cancer Survivors — I
Zhou Y, Irwin ML, Ferrucci LM, McCorkle R, Ercolano EA, Li F, Stein K, Cartmel B. Health-related quality of life in ovarian cancer survivors: Results from the American Cancer Society's Study of Cancer Survivors — I. Gynecologic Oncology 2016, 141: 543-549. PMID: 27072805, PMCID: PMC4913461, DOI: 10.1016/j.ygyno.2016.04.006.Peer-Reviewed Original ResearchConceptsOvarian cancer survivorsGreater symptom burdenAmerican Cancer Society's StudyHealth-related qualityCancer survivorsSymptom burdenDisease recurrencePhysical functioningTwo yearsOne-yearPredictors of HRQOLNumber of comorbiditiesHigher disease stagePhysical HRQoL scoresPoor mental functioningSubset of participantsMental health issuesMental functioningMore comorbiditiesHRQoL scoresClinical factorsLower HRQoLDisease stageHRQoL dataSecondary data analysis
1999
Plasma Lycopene Concentrations in Humans Are Determined by Lycopene Intake, Plasma Cholesterol Concentrations and Selected Demographic Factors 1 , 2
Mayne S, Cartmel B, Silva F, Kim C, Fallon B, Briskin K, Zheng T, Baum M, Shor-Posner G, Goodwin W. Plasma Lycopene Concentrations in Humans Are Determined by Lycopene Intake, Plasma Cholesterol Concentrations and Selected Demographic Factors 1 , 2. Journal Of Nutrition 1999, 129: 849-854. PMID: 10203560, DOI: 10.1093/jn/129.4.849.Peer-Reviewed Original ResearchConceptsPlasma lycopene levelsPlasma lycopene concentrationsPlasma cholesterolLycopene levelsPlasma lycopeneLycopene intakeLycopene concentrationHigher plasma lycopene concentrationsNonwhite race/ethnicityDietary lycopene intakeCancer Prevention TrialMarital statusLow dietary intakeLower plasma cholesterolPlasma cholesterol concentrationLow plasma concentrationsLess vitamin CRace/ethnicityPrevention trialsDietary lycopeneTriglyceride levelsUnivariate analysisDietary intakeChronic diseasesPlasma concentrations